- Home
- DXR vs COCH Comparison
DXR vs COCH Comparison
Compare DXR & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DXR | COCH |
|---|---|---|
| Founded | 1970 | 1995 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Medical/Dental Instruments | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.0M | 49.7M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | DXR | COCH |
|---|---|---|
| Price | $10.73 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 7.8K | ★ 119.6K |
| Earning Date | 02-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,446,345.00 | N/A |
| Revenue This Year | $44,935.22 | $1.58 |
| Revenue Next Year | $74.79 | N/A |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.29 | $0.36 |
| 52 Week High | $14.76 | $1.89 |
Technical Indicators
Market Signals| Indicator | DXR | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 49.40 | 49.75 |
| Support Level | $9.11 | $0.64 |
| Resistance Level | $11.79 | $0.73 |
| Average True Range (ATR) | 0.74 | 0.03 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 28.54 | 39.40 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.